240 related articles for article (PubMed ID: 28130758)
1. HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study.
Talamonti M; Galluzzo M; Zangrilli A; Papoutsaki M; Egan CG; Bavetta M; Tambone S; Fargnoli MC; Bianchi L
Mol Diagn Ther; 2017 Jun; 21(3):295-301. PubMed ID: 28130758
[TBL] [Abstract][Full Text] [Related]
2. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study.
Costanzo A; Bianchi L; Flori ML; Malara G; Stingeni L; Bartezaghi M; Carraro L; Castellino G;
Br J Dermatol; 2018 Nov; 179(5):1072-1080. PubMed ID: 29704432
[TBL] [Abstract][Full Text] [Related]
3. Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study.
Talamonti M; Galluzzo M; Bernardini N; Caldarola G; Persechino S; Cantoresi F; Egan CG; Potenza C; Peris K; Bianchi L
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1737-1744. PubMed ID: 29776016
[TBL] [Abstract][Full Text] [Related]
4. HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis.
Dand N; Duckworth M; Baudry D; Russell A; Curtis CJ; Lee SH; Evans I; Mason KJ; Alsharqi A; Becher G; Burden AD; Goodwin RG; McKenna K; Murphy R; Perera GK; Rotarescu R; Wahie S; Wright A; Reynolds NJ; Warren RB; Griffiths CEM; Smith CH; Simpson MA; Barker JN; ; ;
J Allergy Clin Immunol; 2019 Jun; 143(6):2120-2130. PubMed ID: 30578879
[TBL] [Abstract][Full Text] [Related]
5. Use of biological drugs in patients with psoriasis and psoriatic arthritis in Italy: Results from the PSONG survey.
Potenza MC; Peris K; Berardesca E; Bianchi L; Richetta A; Bernardini N; De Simone C; Teoli M; Zangrilli A; D'epiro S; Orsini D; Narcisi A; Chimenti S; Costanzo A
Dermatol Ther; 2018 Jan; 31(1):. PubMed ID: 29215183
[TBL] [Abstract][Full Text] [Related]
6. PACE study: real-life Psoriasis Area and Severity Index (PASI) 100 response with biological agents in moderate-severe psoriasis.
Carrera CG; Dapavo P; Malagoli P; Naldi L; Arancio L; Gaiani F; Egan CG; Di Mercurio M; Cattaneo A
J Dermatolog Treat; 2018 Aug; 29(5):481-486. PubMed ID: 29058948
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab.
Talamonti M; Botti E; Galluzzo M; Teoli M; Spallone G; Bavetta M; Chimenti S; Costanzo A
Br J Dermatol; 2013 Aug; 169(2):458-63. PubMed ID: 23521149
[TBL] [Abstract][Full Text] [Related]
8. Role of the HLA-C*06 allele in clinical response to ustekinumab: evidence from real life in a large cohort of European patients.
Talamonti M; Galluzzo M; van den Reek JM; de Jong EM; Lambert JLW; Malagoli P; Bianchi L; Costanzo A
Br J Dermatol; 2017 Aug; 177(2):489-496. PubMed ID: 28207934
[TBL] [Abstract][Full Text] [Related]
9. NFKBIZ and CW6 in Adalimumab Response Among Psoriasis Patients: Genetic Association and Alternative Transcript Analysis.
Coto-Segura P; González-Lara L; Batalla A; Eiris N; Queiro R; Coto E
Mol Diagn Ther; 2019 Oct; 23(5):627-633. PubMed ID: 31267486
[TBL] [Abstract][Full Text] [Related]
10. Genetic markers of treatment response to tumour necrosis factor-α inhibitors in the treatment of psoriasis.
Ryan C; Kelleher J; Fagan MF; Rogers S; Collins P; Barker JN; Allen M; Hagan R; Renfro L; Kirby B
Clin Exp Dermatol; 2014 Jun; 39(4):519-24. PubMed ID: 24758522
[TBL] [Abstract][Full Text] [Related]
11. HLA-C*06:02 Allele and Response to IL-12/23 Inhibition: Results from the Ustekinumab Phase 3 Psoriasis Program.
Li K; Huang CC; Randazzo B; Li S; Szapary P; Curran M; Campbell K; Brodmerkel C
J Invest Dermatol; 2016 Dec; 136(12):2364-2371. PubMed ID: 27476722
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment of psoriatic patients with adalimumab reduces disease severity and maintains a favorable lipid pattern and a low Atherogenic Index.
Zangrilli A; Bavetta M; Scaramella M; Bianchi L
G Ital Dermatol Venereol; 2018 Apr; 153(2):146-154. PubMed ID: 29564871
[TBL] [Abstract][Full Text] [Related]
13. Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis.
van den Reek JMPA; Coenen MJH; van de L'Isle Arias M; Zweegers J; Rodijk-Olthuis D; Schalkwijk J; Vermeulen SH; Joosten I; van de Kerkhof PCM; Seyger MMB; Zeeuwen PLJM; de Jong EMGJ
Br J Dermatol; 2017 May; 176(5):1288-1296. PubMed ID: 27564082
[TBL] [Abstract][Full Text] [Related]
14. Serum C-reactive protein levels in Japanese patients with psoriasis and psoriatic arthritis: Long-term differential effects of biologics.
Asahina A; Umezawa Y; Yanaba K; Nakagawa H
J Dermatol; 2016 Jul; 43(7):779-84. PubMed ID: 26704718
[TBL] [Abstract][Full Text] [Related]
15. Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12/23 blocker, in Chinese patients with psoriasis: a retrospective analysis.
Chiu HY; Wang TS; Chan CC; Cheng YP; Lin SJ; Tsai TF
Br J Dermatol; 2014 Nov; 171(5):1181-8. PubMed ID: 24734995
[TBL] [Abstract][Full Text] [Related]
16. Long-term efficacy and safety of adalimumab in patients with moderate to severe psoriasis treated continuously over 3 years: results from an open-label extension study for patients from REVEAL.
Gordon K; Papp K; Poulin Y; Gu Y; Rozzo S; Sasso EH
J Am Acad Dermatol; 2012 Feb; 66(2):241-51. PubMed ID: 21752491
[TBL] [Abstract][Full Text] [Related]
17. Anti-TNF-α therapy improves insulin sensitivity in non-diabetic patients with psoriasis: a 6-month prospective study.
Pina T; Armesto S; Lopez-Mejias R; Genre F; Ubilla B; Gonzalez-Lopez MA; Gonzalez-Vela MC; Corrales A; Blanco R; Garcia-Unzueta MT; Hernandez JL; Llorca J; Gonzalez-Gay MA
J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1325-30. PubMed ID: 25353352
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial.
Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB
J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361
[TBL] [Abstract][Full Text] [Related]
19. A multicenter open-label experience on the response of psoriasis to Adalimumab and effect of dose escalation in non-responders: the Aphrodite project.
Vena GA; Galluccio A; De Simone C; Mastrandrea V; Buquicchio R; La Greca S; Dattola S; Puglisi Guerra A; Donato L; Cantoresi F; De Pità O; Pezza M; D Agostino M; Vernaci R; Miracapillo A; Valenti G; Cassano N
Int J Immunopathol Pharmacol; 2009; 22(1):227-33. PubMed ID: 19309570
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of adalimumab in psoriatic patients previously treated with etanercept in a real-world setting.
Fonseca E; Iglesias R; Paradela S; Fernández-Torres RM; Elberdín L
J Dermatolog Treat; 2015 Jun; 26(3):217-22. PubMed ID: 24920071
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]